Category: Wall Street BeatSyndicate content

Allergan pushes to kick Valeant, Pershing out of special shareholder meeting

September 16, 2014 by Arezu Sarvestani

Allergan is still looking to prevent Valeant Pharmaceuticals and Pershing Square from voting their shares in a December 18 shareholder meeting the company was forced to host.

Allergan cedes to shareholder meeting, but still pushes for injunction

Danaher becomes dental giant with $2.1B Nobel Biocare buy

September 15, 2014 by Arezu Sarvestani

The $2.14 billion acquisition of Nobel Biocare will turn Danaher into the largest dental implants provider in the world.

Danaher becomes dental giant with $2.1B Nobel Biocare buy

Second suitor ceded early to Zimmer in chase for Biomet

September 12, 2014 by Brad Perriello

A 2nd suitor for orthopedic device maker Biomet ceded the field early to Zimmer, regulatory filings show, but Biomet held out for better terms from its cross-town rival.

Second suitor ceded early to Zimmer in chase for Biomet

ReWalk Robotics prices IPO at $36M, below range

September 12, 2014 by Brad Perriello

ReWalk Robotics prices its initial public offering at $12 a share, under its prior range, raising $36 million for its exoskeleton for spinal cord injury patients

ReWalk Robotics prices IPO at $36M, below range

ReWalk Robotics (NSDQ:RWLK) priced its initial public offering below its forecast range, at $12 per share, grossing some $36.0 million for its exo-skeleton suit.

Mevion Medical files for $69M IPO

September 12, 2014 by Brad Perriello

Mevion Medical looks to go public with a $69 million stock offering as it gears up to scale its proton therapy device.

Mevion Medical files for $69M IPO

Mevion Medical registered for a $69 million initial public offering as it gears up to commercialize its proton therapy system.

Kimberly-Clark readies Halyard Health medical device spinout

September 11, 2014 by Brad Perriello

Halyard Health, the publicly traded, $1.6 billion spinout of Kimberly-Clark's medical device business, is slated to go live in November, soon-to-be COO Chris Lowery tells MassDevice.com.

Kimberly-Clark readies Halyard Health medical device spinout

InVivo's stock drops as ex-CEO dumps shares

September 11, 2014 by Arezu Sarvestani

InVivo Therapeutics ex-CEO Frank Reynolds has been liquidating his position in the company, putting even more weight on NVIV's already-pressured shares.

InVivo's stock drops as ex-CEO dumps shares

As if InVivo Therapeutics (OTC:NVIV) wasn't having a tough enough time already, the company's stock is under even more pressure as former CEO Frank Reynolds has been liquidating his position over the last few weeks.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp